Skip to content

Effect of Consumption of Non Caloric Sweeteners and Insulin Sensibility

Effect of Consumption of Non Caloric Sweeteners and Insulin Sensibility

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02890108
Enrollment
10
Registered
2016-09-07
Start date
2016-08-31
Completion date
2016-10-31
Last updated
2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Sensitivity

Keywords

High-Intensity Sweeteners, Non-Nutritive Sweeteners, Artificial sweeteners, Glucose intolerance

Brief summary

This study will compare the effect of acute consumption of two carbonated drinks, sweetened with sugar or with non-caloric sweeteners, over the insulin response of healthy adults who normally consumed foods or drinks that contain non-caloric sweeteners

Detailed description

During the last decades there has been a sustained increase in prevalence of overweight and obesity and, along with it, of chronic noncommunicable diseases. There have been addressed various management strategies, including sugar replacement for Non-caloric Artificial Sweeteners (NAS). Nevertheless, in several cohort studies it has found the opposite effect, it has observed associations between the consumption of NAS with greater weight gain and increased risk of type 2 diabetes and metabolic syndrome. In clinical trials, in both humans and mice, there has been greater association with glucose intolerance, being 3 possible mechanisms: 1) dysbiosis of the intestinal microbiota; 2) altered regulation of appetite cephalic phase and secretion of glucagon like peptide-1 (GLP-1); and 3) increased intestinal glucose absorption via increased Sodium-Glucose Linked Transporter-1 (SGLT-1) and Glucose transporter 2 (GLUT2), transporters to glucose absorption. In the following review the major findings in the literature regarding the consumption of NAS and its deleterious effects on human health will be studied.

Interventions

DIETARY_SUPPLEMENTSugar sweetened beverages

350 cc (1 can) of sugar sweetened beverage

350 cc (1 can) of artificially sweetened beverage

Sponsors

Instituto de Nutrición y Tecnología de los Alimentos
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Body Mass Index (BMI) between 18,5 - 24,9 kg/mt2 * Healthy men or women * Fasting plasma glucose \< 100 mg/dL

Exclusion criteria

* Consumption of drugs affecting glucose metabolism, antihypertensives or lipid lowering * Subjects with insulin resistance, type 1 or 2 diabetes, dyslipidemia, hypertension; heart, liver or kidney disease, respiratory failure, stroke, or any chronic illness. * Pregnant women. * Being treated to gain or lose weight. * History of recurrent episodes of acute diarrhea.

Design outcomes

Primary

MeasureTime frameDescription
Insulin sensibilityMeasured at 6 intervals (3 times sugar sweetened beverages and 3 times artificially sweetened beverages), separated at least by 1 week from each other. All the tests must be assessed during 10 weeks utmost.One insulinemic curve will be conducted to assess the effect of consumption of artificially sweetened beverage on insulin response compared to the consumption of a sugar sweetened drink.

Secondary

MeasureTime frameDescription
Glycemic responseMeasured at 6 intervals (3 times sugar sweetened beverages and 3 times artificially sweetened beverages), separated at least by 1 week from each other. All the tests must be assessed during 10 weeks utmost.One glycemic curve will be conducted to assess the effect of consumption of artificially sweetened beverage on glycemic response compared to the consumption of a sugar sweetened drink.

Countries

Chile

Contacts

Primary ContactRomina A Goza Ferreira, Magister c
rominagoza@gmail.com+56950088329
Backup ContactSandra Hirsch Birn, Magister
shirsch@inta.uchile.cl+56229781495

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026